The Japanese Ministry of Health (MOH) has approved Nectar Lifesciences to market Cefuroxime Axetil molecules to treat bacterial infection.
Subscribe to our email newsletter
Nectar Lifesciences is a research driven pharmaceutical organization, engaged in manufacturing and delivering pharmaceutical products.
Nectar Lifesciences CEO and director said the Japanese audit is one of the most stringent globally and the fact that they have been approved by the Japanese MOH marks their journey in the regulated path.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.